הלוואות ואשראי לטווח ארוך של החברה Windtree Therapeutics, Inc. (WINT)
Windtree Therapeutics (WINT) is a cardiology developer facing liquidity shortages and concerns regarding business viability due to potential test failures. The model relies on outsourcing production and research, which relieves the team of infrastructure costs. This price chart reflects debts at the level of 0.00. The company is currently preparing the results of phase II trials for heart failure treatments while maintaining a stable pace of innovation.
WINT (Windtree Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Windtree Therapeutics (WINT) develops innovative cardiology drugs for the emergency treatment of heart failure. The high cost of such R&D projects necessitates the attraction of debt capital, which is reflected in the liability structure. This metric aggregates all credit claims with a maturity of more than one year, measuring the long-term financial burden. Rising debt finances expansion but increases liquidity risk. An analysis of the company's long-term debt allows for an assessment of the credit portfolio's stability.